LIPO · Lipella Pharmaceuticals Inc. · Share Buybacks
Substantial doubt about the company's ability to continue as a going concern.
“These factors individually and collectively raise substantial doubt about the Company's ability to continue as a going concern. The accompanying unaudited condensed financial statements do not include any adjustments that may result from this uncertainty.”View the 10-Q filed Nov 14, 2025
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2025-04-04 | — | $2,641,881 | — | — | 10-Q , filed 2025-08-14 |